SUNNYVALE, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming William Blair 45th Annual Growth Stock Conference. The presentation will take place on Tuesday, June 3, 2025, at 7:20 a.m. Pacific Standard Time / 9:20 a.m. Central Standard Time. Event: William ...

Core Insights - CeriBell, Inc. reported a strong financial performance for Q1 2025, with total revenue reaching $20.5 million, a 42% increase from $14.4 million in Q1 2024, driven by new account adoption and expansion within existing accounts [4][11] - The company is optimistic about continued growth in 2025, focusing on physician education and product development, including the introduction of a pediatric Clarity algorithm [3][8] Financial Performance - Total revenue for Q1 2025 was $20.5 million, up 42% from $14.4 million in Q1 2024, with product revenue at $15.6 million (41% increase) and subscription revenue at $4.9 million (45% increase) [4][15] - Gross profit for Q1 2025 was $18.0 million, with a gross margin of 88%, compared to $12.3 million and 86% in Q1 2024 [5][11] - Operating expenses increased by 55% to $32.2 million in Q1 2025, primarily due to investments in the commercial organization and increased headcount [6][11] - The net loss for Q1 2025 was $12.8 million, or $0.36 per share, compared to a net loss of $8.5 million, or $1.56 per share, in Q1 2024 [7][11] Future Outlook - CeriBell raised its revenue guidance for the full year 2025 to a range of $83 million to $87 million, indicating a growth of approximately 27% to 33% over the previous year [8] - The company ended Q1 2025 with 558 total active accounts and received FDA clearance for the expansion of its Clarity algorithm, marking a significant milestone [11][11] Company Overview - CeriBell is a medical technology company focused on transforming the diagnosis and management of serious neurological conditions through its innovative EEG platform [13]

SUNNYVALE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming Bank of America Securities 2025 Health Care Conference. The presentation will take place on Wednesday, May 14, 2025, at 10:55 a.m. Pacific Standard Time / 1:55 p.m. Eastern Standard Time. Event ...

Ceribell is one of only 51 companies in the U.S. to achieve FedRAMP High authorization Ceribell's breakthrough technology can now be deployed in federal healthcare facilities, including U.S. Department of Veterans Affairs hospitals, helping clinicians deliver faster diagnosis and treatment for patients at risk of non-convulsive seizures SUNNYVALE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company transforming the diagnosis and management of p ...

CeriBell, Inc. (NASDAQ:CBLL) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Brian Johnston - Gilmartin Group Xingjuan Chao - President and Chief Executive Officer Scott Blumberg - Chief Financial Officer Conference Call Participants Stephanie Piazzola - Bank of America Robert Marcus - JPMorgan Chase & Co. Macauley Kilbane - William Blair & Company Joshua Jennings - TD Cowen William Plovanic - Canaccord Genuity Corp. Operator Operator Hello, and thank you for standing by. ...